Amgen Inc (NAS:AMGN)
$ 308.45 -1.7 (-0.55%) Market Cap: 165.46 Bil Enterprise Value: 220.69 Bil PE Ratio: 44.06 PB Ratio: 32.95 GF Score: 89/100

Amgen Inc at Cowen Immuno-Oncology Next Summit Transcript

Nov 13, 2020 / 08:30PM GMT
Release Date Price: $237.36 (+0.09%)
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Good afternoon, everybody, and thank you once again for joining us for the Fourth Annual IO Summary that coincides with the SITC conference. I'm Yaron Werber, Biotech Analyst here at Cowen. And it's a great pleasure to moderate the last session of the day with Amgen. We have 2 gentlemen that really need no introduction. David Reese is Chief Medical Officer; and Arvind Sood is VP of Investor Relations. Gentlemen, thanks so much for joining us. We appreciate it.

David M. Reese
Amgen Inc. - EVP of Research & Development

Thank you, Yaron. And just for clarity, I'm Head of R&D, not, in fact, our Chief Medical Officer.

Yaron Benjamin Werber;David M. Reese
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst;Amgen Inc. - EVP of Research & Development<

That is correct. I've been so used to saying Chief Medical Officer all day today, I apologize.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot